Halozyme Therapeutics, Inc. (HALO) Earnings History
Annual and quarterly earnings data from 2001 to 2025
Loading earnings history...
HALO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
HALO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 78.1% | 58.4% | 22.7% |
| 2024 | 84.3% | 54.3% | 43.7% |
| 2023 | 76.8% | 40.7% | 34.0% |
| 2022 | 78.9% | 40.5% | 30.6% |
| 2021 | 81.6% | 62.2% | 90.8% |
Download Data
Export HALO earnings history in CSV or JSON format
Free sign-in required to download data
Halozyme Therapeutics, Inc. (HALO) Earnings Overview
As of May 8, 2026, Halozyme Therapeutics, Inc. (HALO) reported trailing twelve-month net income of $317M, reflecting -25.4% year-over-year growth. The company earned $2.69 per diluted share over the past four quarters, with a net profit margin of 22.7%.
Looking at the long-term picture, HALO's 5-year EPS compound annual growth rate (CAGR) stands at +23.0%, indicating exceptional earnings growth. The company achieved its highest annual net income of $444M in fiscal 2024.
Halozyme Therapeutics, Inc. maintains industry-leading profitability with a gross margin of 78.1%, operating margin of 58.4%, and net margin of 22.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), IONS (-$327M net income, -40.4% margin), ARWR (-$301M net income, -0.2% margin), HALO has outperformed on profitability metrics. Compare HALO vs ALNY →
HALO Earnings vs Peers
Earnings metrics vs comparable public companies
HALO Historical Earnings Data (2001–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $317M | -28.6% | $816M | $2.56 | 22.7% | 58.4% |
| 2024 | $444M | +57.7% | $551M | $3.43 | 43.7% | 54.3% |
| 2023 | $282M | +39.3% | $338M | $2.10 | 34.0% | 40.7% |
| 2022 | $202M | -49.8% | $268M | $1.44 | 30.6% | 40.5% |
| 2021 | $403M | +212.0% | $276M | $2.74 | 90.8% | 62.2% |
| 2020 | $129M | +278.7% | $144M | $0.91 | 48.2% | 53.9% |
| 2019 | -$72M | +10.1% | -$68M | $-0.50 | -36.9% | -34.5% |
| 2018 | -$80M | -227.6% | -$69M | $-0.56 | -52.9% | -45.7% |
| 2017 | $63M | +161.1% | $81M | $0.45 | 19.9% | 25.6% |
| 2016 | -$103M | -219.6% | -$83M | $-0.81 | -70.2% | -56.7% |
See HALO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HALO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HALO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHALO — Frequently Asked Questions
Quick answers to the most common questions about buying HALO stock.
Is HALO growing earnings?
HALO EPS fell to $2.69, with earnings declining -25.4%. This contrasts with the 5-year CAGR of +23.0%. TTM net income dropped to $317M.
What are HALO's profit margins?
Halozyme Therapeutics, Inc. net margin is +22.7%, with operating margin at +58.4%. Above-average margins indicate pricing power.
How consistent are HALO's earnings?
HALO earnings data spans 2001-2025. The declining earnings trend is -25.4% YoY. Historical data enables comparison across business cycles.